Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.
The pharmacokinetics of cefroxadine was studied in 17 patients with terminal renal impairment, 10 of whom were undergoing 5 h dialysis sessions. The antibiotic was administered as a single oral dose of 500 mg. Cefroxadine followed a single compartment open kinetic model. During the interdialysis period in patients with terminal renal impairment, an average Cmax of 26.59 micrograms/ml and a tmax of 3.65 h were reached, which are greater than in patients with normal renal function. The serum half-life was reduced from 23.55 h in the interdialysis periods to 3.40 h during the dialysis sessions. The average extraction coefficient was 0.249. It is recommended that a 500 mg dose cefroxadine should be administered at the end of each dialysis session if the interdialysis period is 48 h.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002511:Cephalosporins / Q000378:metabolism*; D002515:Cephradine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D002511:Cephalosporins; C012671:cefroxadine; D002515:Cephradine